diff --git a/apps/docs/scripts/auth-cli.ts b/apps/docs/scripts/auth-cli.ts index e2406e5..a742945 100644 --- a/apps/docs/scripts/auth-cli.ts +++ b/apps/docs/scripts/auth-cli.ts @@ -184,7 +184,7 @@ async function main() { const research = await researchResponse.json(); assert.equal(research.companies.length, 1039); assert.equal(research.categories.length, 11); - assert.equal(research.evidence.length, 1512); + assert.equal(research.evidence.length, 1531); assert.equal(research.observations.length, 207); assert.equal((await request("/api/research/ai-companies", { method: "POST", headers })).status, 405); const researchPage = await request("/docs/other-research/ai-company-research/overview", { headers }); diff --git a/apps/docs/tests/research.test.ts b/apps/docs/tests/research.test.ts index 004ed19..7bd0d49 100644 --- a/apps/docs/tests/research.test.ts +++ b/apps/docs/tests/research.test.ts @@ -24,7 +24,7 @@ test("research revisions share the authentication database and preserve replay l assert.equal(consumeCode(config, "invalid"), "limited"); const initial = readResearchSnapshot(); assert.equal(initial.companies.length, 1039); - assert.equal(initial.evidence.length, 1512); + assert.equal(initial.evidence.length, 1531); assert.equal(initial.observations.length, 207); assert.deepEqual(initial.candidateBatches, seed.candidateBatches, "candidate gaps persist in the same database metadata"); assert.deepEqual(initial.directoryRechecks, seed.directoryRechecks, "follow-up classifications persist without rewriting the discovery audit"); @@ -66,7 +66,7 @@ test("reviews link explicit companies without turning global or excluded cases i const snapshot = structuredClone(seed) as ResearchSnapshot; assert.equal(snapshot.reviews.filter((r) => r.scope === "companies").length, 87); assert.equal(snapshot.reviews.filter((r) => r.scope === "dataset").length, 10); - assert.equal(snapshot.reviews.filter((r) => r.scope === "excluded-candidate").length, 40); + assert.equal(snapshot.reviews.filter((r) => r.scope === "excluded-candidate").length, 41); const review = snapshot.reviews.find((r) => r.id === "R4")!; assert.deepEqual(reviewCompanyIds(snapshot, review), ["AI007", "AI013", "AI021", "AI034"]); assert.deepEqual(reviewCompanyIds(snapshot, snapshot.reviews.find((r) => r.id === "CN-R-PSI")!), []); @@ -327,7 +327,7 @@ test("unreconciled directory financials remain source reviews instead of income assert.ok(review.evidenceIds.includes("PH-TANA-DR")); assert.equal(reviewCompanyIds(snapshot, review).length, 0); assert.ok(!snapshot.observations.some((o) => o.evidence === "PH-TANA-DR")); - assert.equal(snapshot.candidateBatches!.flatMap((b) => b.records).filter((r) => r.status === "pending-year").length, 20); + assert.equal(snapshot.candidateBatches!.flatMap((b) => b.records).filter((r) => r.status === "pending-year").length, 21); }); test("product pivots and founder histories do not become new company years or current revenue", () => { diff --git a/content/research/ai-companies.seed.json b/content/research/ai-companies.seed.json index 207637e..eaf6cb9 100644 --- a/content/research/ai-companies.seed.json +++ b/content/research/ai-companies.seed.json @@ -1,5 +1,5 @@ { - "version": "2026-10-30-tc-finance-1", + "version": "2026-10-30-tc-biotech-1", "asOf": "2026-10-30", "scope": "全球公开资料研究：保留首批个案，并扩展核查2025—2026八个YC批次候选池；成立年份以官方公司页面字段为依据。", "limitations": [ @@ -49626,6 +49626,215 @@ "kind": "公司官方资料", "summary": "自述Founded 2024，链接zownhomes.com；说明买家补助由赚取佣金支持。", "limitation": "地域、合作经纪及返佣后的净额分摊未核，不把员工档案或客户交易数当订阅数。" + }, + { + "id": "TC25-BIO-LIST", + "companyId": null, + "title": "2025生物技术参赛名单登记", + "url": "https://techcrunch.com/2025/12/24/the-9-top-biotech-startups-from-disrupt-startup-battlefield/", + "publishedAt": null, + "accessedAt": "2026-10-30", + "kind": "媒体名单读取", + "summary": "仅作为候选发现入口。", + "limitation": "参赛年不是成立年，业务和阶段另读原始资料；不把生物技术类别直接等同AI公司。" + }, + { + "id": "TC25-BIO-CASNX-HOME", + "companyId": null, + "title": "CasNx器官工程研发", + "url": "https://www.casnx.com/", + "publishedAt": null, + "accessedAt": "2026-10-30", + "kind": "公司官方资料", + "summary": "在体外供体器官上研发CRISPR处理，官网链接科学出版物及研究合作入口。", + "limitation": "研究论文、合作和未来器官疗法不当商业收入或获批产品；当前AI核心角色未专项核实。" + }, + { + "id": "TC25-BIO-CASNX-YEAR", + "companyId": null, + "title": "UF孵化方CasNx沿革", + "url": "https://innovate.research.ufl.edu/uf-researchers-rewriting-organ-biology-with-revolutionary-transplant-technology/", + "publishedAt": null, + "accessedAt": "2026-10-30", + "kind": "大学孵化机构原始介绍", + "summary": "UF Innovate 2025-08-19介绍其客户公司CasNx于2024年成立。", + "limitation": "机构介绍不是精确注册核验；基础研究与公司能力、未来临床价值及收入分开。" + }, + { + "id": "TC25-BIO-CHIPIRON-HOME", + "companyId": null, + "title": "Chipiron MRI与历史里程碑", + "url": "https://www.chipiron.co/", + "publishedAt": null, + "accessedAt": "2026-10-30", + "kind": "公司官方资料", + "summary": "研发超低场MRI，官网自述AI降噪及图像重建，并列2023—2024技术和融资沿革。", + "limitation": "2026—2028验证、临床与FDA路线图是计划；截至研究日不当已经完成审批。融资、补助不作收入，设备与软件持续收费需拆分。" + }, + { + "id": "TC25-BIO-EXACTICS-HOME", + "companyId": null, + "title": "Exactics诊断产品", + "url": "https://www.exacticsbiotech.com/", + "publishedAt": null, + "accessedAt": "2026-10-30", + "kind": "公司官方资料", + "summary": "研发家庭诊断工具，官网列原型、团队和大学合作。", + "limitation": "专利、融资、市场规模与产品研发不是收入；未确认当前AI核心交付或临床性能，不与同名模具企业合并。" + }, + { + "id": "TC25-BIO-EXACTICS-YEAR", + "companyId": null, + "title": "Exactics公司公开主页", + "url": "https://www.linkedin.com/company/exactics", + "publishedAt": null, + "accessedAt": "2026-10-30", + "kind": "公司官方资料", + "summary": "自述Founded 2021，链接exacticsbiotech.com。", + "limitation": "精确注册日未核；老About链接现跳转团队页，不把旧检索内容当当前全文。" + }, + { + "id": "TC25-BIO-AVARA-ACCESS", + "companyId": null, + "title": "Avara官网访问缺项", + "url": "https://avarabio.com/", + "publishedAt": null, + "accessedAt": "2026-10-30", + "kind": "公司官网访问缺项", + "summary": "当前仅取得wellness device标题，正文不可读。", + "limitation": "不据标题确认完整功能、AI作用、销量或医疗验证。" + }, + { + "id": "TC25-BIO-AVARA-TERMS-ACCESS", + "companyId": null, + "title": "Avara运营者线索与访问缺项", + "url": "https://avarabio.com/terms", + "publishedAt": null, + "accessedAt": "2026-10-30", + "kind": "公司官方条款访问缺项", + "summary": "检索可见Lumos Strategies OÜ运营者线索，直达正文为空。", + "limitation": "未将检索摘录当已读条款，需补可读主体链接与AI交付；条款更新日期不是成立年。" + }, + { + "id": "TC25-BIO-LUMOS-REGISTRY", + "companyId": null, + "title": "Lumos Strategies同名官方登记", + "url": "https://ariregister.rik.ee/eng/company/17138613", + "publishedAt": null, + "accessedAt": "2026-10-30", + "kind": "官方公司登记", + "summary": "爱沙尼亚官方登记列Lumos Strategies OÜ注册于2024-12-19，登记号17138613。", + "limitation": "登记可读，但Avara条款正文空白，尚未以可读官网或登记号完成产品—运营者对应；不按名称直接合并主体，未解读删除公告为已注销。" + }, + { + "id": "TC25-BIO-MIRAQULES-HOME", + "companyId": null, + "title": "Miraqules止血材料及沿革", + "url": "https://www.miraqules.com/", + "publishedAt": null, + "accessedAt": "2026-10-30", + "kind": "公司官方资料", + "summary": "官方介绍止血生物材料及StopBleed，自述2018年起步。", + "limitation": "当前页夹有模板内容；不当AI模型或临床独立验证，效果倍数、获资助与市场不作收入。" + }, + { + "id": "TC25-BIO-NEPHROGEN-HOME", + "companyId": null, + "title": "Nephrogen AI筛选研发", + "url": "https://www.nephrogenbiotech.com/", + "publishedAt": null, + "accessedAt": "2026-10-30", + "kind": "公司官方资料", + "summary": "自述AI结合高通量筛选，研发肾脏与胰腺基因递送载体，官网列科研出版物。", + "limitation": "体外/动物或组织研究不等获批治疗；性能倍数、药企赞助和合作资金不自动等ARR，旧研究及顾问履历与公司交付分开。" + }, + { + "id": "TC25-BIO-NEPHROGEN-YC", + "companyId": null, + "title": "Nephrogen机构年份与批次", + "url": "https://www.ycombinator.com/companies/nephrogen", + "publishedAt": null, + "accessedAt": "2026-10-30", + "kind": "投资孵化机构名录", + "summary": "YC列Founded 2022、Summer 2020，当前域名一致。", + "limitation": "年份与批次时序不一致，精确成立链待核；两项均早于2025，不根据2025参赛新增公司。" + }, + { + "id": "TC25-BIO-PRAXISPRO-HOME", + "companyId": null, + "title": "PraxisPro生命科学商业团队软件", + "url": "https://www.praxispro.ai/", + "publishedAt": null, + "accessedAt": "2026-10-30", + "kind": "公司官方资料", + "summary": "为药企及器械团队提供AI角色扮演、准备度认证和教练工作流。", + "limitation": "客户培训收益和药品销售不是公司收入；不因生命科学买家归药物研发模型，合规及效果宣传未独立核。" + }, + { + "id": "TC25-BIO-PRAXISPRO-YEAR", + "companyId": null, + "title": "PraxisPro公司公开主页", + "url": "https://www.linkedin.com/company/praxispro-ai", + "publishedAt": null, + "accessedAt": "2026-10-30", + "kind": "公司官方资料", + "summary": "自述Founded 2023，域名praxispro.ai对应，主营商业团队智能。", + "limitation": "公司自述而非精确登记；模型专用宣传不等独立能力验证，团队范围不填精确人数。" + }, + { + "id": "TC25-BIO-REMED-HOME", + "companyId": null, + "title": "Reme-D诊断试剂", + "url": "https://reme-d-inc.com/", + "publishedAt": null, + "accessedAt": "2026-10-30", + "kind": "公司官方资料", + "summary": "研发及制造人和动物疾病分子诊断、核酸提取及检测工具。", + "limitation": "未核AI核心交付；试剂销售、仪器和研究服务收费需拆分，检测人数或社会效益不等收入。" + }, + { + "id": "TC25-BIO-REMED-HISTORY", + "companyId": null, + "title": "Reme-D早期官方业务记录", + "url": "https://reme-d-inc.com/reme-d-is-a-winner-in-the-falling-walls-science-venture/", + "publishedAt": null, + "accessedAt": "2026-10-30", + "kind": "公司官方资料", + "summary": "官网记Science Summit 2024的Reme-D业务获奖活动。", + "limitation": "仅证明更早业务沿革，不当精确注册、临床获批或独立性能验证。" + }, + { + "id": "TC25-BIO-REMED-YEAR-ACCESS", + "companyId": null, + "title": "Reme-D机构年份读取缺项", + "url": "https://jobs.techstars.com/companies/reme-d", + "publishedAt": null, + "accessedAt": "2026-10-30", + "kind": "机构原始资料访问缺项", + "summary": "检索有2022成立线索，直达Cache miss。", + "limitation": "不当完整机构页已读，精确注册及不同地区主体链留缺；范围外以官方2024业务材料补证。" + }, + { + "id": "TC25-BIO-SURGICURE-HOME", + "companyId": null, + "title": "Surgicure医疗器械", + "url": "https://www.surgicuretech.com/", + "publishedAt": null, + "accessedAt": "2026-10-30", + "kind": "公司官方资料", + "summary": "HORSESHOE气管导管固定器械，官网列Surgicure Technologies, Inc.。", + "limitation": "当前AI核心角色未确认；医院避免损失、ROI估计及安全宣传不等公司收入，不能从专利或Demo推独立临床效果。" + }, + { + "id": "TC25-BIO-SURGICURE-SEC", + "companyId": null, + "title": "Surgicure原始发行申报", + "url": "https://www.sec.gov/Archives/edgar/data/2038291/000203829124000004/xslFormDX08/primary_doc.xml", + "publishedAt": null, + "accessedAt": "2026-10-30", + "kind": "监管原始申报", + "summary": "发行人Surgicure Technologies, Inc.申报Delaware、2019年组织成立，CIK2038291。", + "limitation": "发行人自报、未经SEC独立审核；不是募资等于经营收入，不能与英国同名医疗公司合并。" } ], "reviews": [ @@ -51751,6 +51960,35 @@ "TC25-FIN-ZOWN-YEAR" ], "handling": "当前官网业务优先于旧描述，订阅、结果收费、地产经纪和AI辅助人工服务分开。标价、ACME演示财务、贷款、存款、房产估值、客户收入和返佣不导入公司ARR；访问失败保留缺项。" + }, + { + "id": "TC25-BIO-R-SCOPE", + "type": "生物技术名单、研发与收入边界", + "company": "2025生物技术参赛候选", + "scope": "excluded-candidate", + "summary": "逐项登记9项：8项范围外/既有业务，1项主体对应待核；没有新增主公司或收入。", + "evidenceIds": [ + "TC25-BIO-LIST", + "TC25-BIO-CASNX-HOME", + "TC25-BIO-CASNX-YEAR", + "TC25-BIO-CHIPIRON-HOME", + "TC25-BIO-EXACTICS-HOME", + "TC25-BIO-EXACTICS-YEAR", + "TC25-BIO-AVARA-ACCESS", + "TC25-BIO-AVARA-TERMS-ACCESS", + "TC25-BIO-LUMOS-REGISTRY", + "TC25-BIO-MIRAQULES-HOME", + "TC25-BIO-NEPHROGEN-HOME", + "TC25-BIO-NEPHROGEN-YC", + "TC25-BIO-PRAXISPRO-HOME", + "TC25-BIO-PRAXISPRO-YEAR", + "TC25-BIO-REMED-HOME", + "TC25-BIO-REMED-HISTORY", + "TC25-BIO-REMED-YEAR-ACCESS", + "TC25-BIO-SURGICURE-HOME", + "TC25-BIO-SURGICURE-SEC" + ], + "handling": "生物技术不直接等AI；治疗、医疗硬件、试剂及商业培训软件按交付分开。论文、临床计划、审批目标、专利、融资、赞助及客户ROI不作已实现ARR或独立验证。Nephrogen批次冲突、Avara空白条款与同名登记、REME-D机构访问缺项保留。" } ], "coverage": { @@ -53812,6 +54050,151 @@ ] } ] + }, + { + "id": "TC-2025-battlefield-biotech-1", + "sourceId": "S02", + "url": "https://techcrunch.com/2025/12/24/the-9-top-biotech-startups-from-disrupt-startup-battlefield/", + "accessedAt": "2026-10-30", + "scope": "本篇9项文字标题均登记并逐项尝试原始官网，8项有研究年份之前的公司或业务资料，Avara/Lumos主体对应待核；逐项保留AI作用、研发阶段、不可读及收入缺项，不等全部参赛者或两年档案。", + "complete": false, + "records": [ + { + "id": "TC25-BIO-01", + "name": "CasNx", + "url": "https://www.casnx.com/", + "categoryId": "C07", + "kind": "company", + "profileStatus": "readable", + "status": "outside-cohort", + "note": "孵化方资料列2024成立，按范围外保留；CRISPR研究不直接认定AI业务或已获批疗法。", + "evidenceIds": [ + "TC25-BIO-LIST", + "TC25-BIO-CASNX-HOME", + "TC25-BIO-CASNX-YEAR" + ] + }, + { + "id": "TC25-BIO-02", + "name": "Chipiron", + "url": "https://www.chipiron.co/", + "categoryId": "C07", + "kind": "company", + "profileStatus": "readable", + "status": "outside-cohort", + "note": "官网有2025前业务里程碑，非本轮新公司；属于医疗成像硬件中的AI，未来审批和商业化计划不当当前交付或ARR。", + "evidenceIds": [ + "TC25-BIO-LIST", + "TC25-BIO-CHIPIRON-HOME" + ] + }, + { + "id": "TC25-BIO-03", + "name": "Exactics", + "url": "https://www.exacticsbiotech.com/", + "categoryId": "C07", + "kind": "company", + "profileStatus": "readable", + "status": "outside-cohort", + "note": "同域名公司主页列2021成立，按既有公司排除；快速诊断不直接当AI或经常性软件收入。", + "evidenceIds": [ + "TC25-BIO-LIST", + "TC25-BIO-EXACTICS-HOME", + "TC25-BIO-EXACTICS-YEAR" + ] + }, + { + "id": "TC25-BIO-04", + "name": "Lumos Strategies OÜ / Avara", + "url": "https://avarabio.com/", + "categoryId": "C00", + "kind": "company", + "profileStatus": "unavailable", + "status": "pending-year", + "note": "同名主体登记2024可读，但Avara官网及条款正文为空；产品、运营者登记号与AI作用未闭合，保留主体/年份核查，不新增公司。", + "evidenceIds": [ + "TC25-BIO-LIST", + "TC25-BIO-AVARA-ACCESS", + "TC25-BIO-AVARA-TERMS-ACCESS", + "TC25-BIO-LUMOS-REGISTRY" + ] + }, + { + "id": "TC25-BIO-05", + "name": "Miraqules", + "url": "https://www.miraqules.com/", + "categoryId": "C07", + "kind": "company", + "profileStatus": "readable", + "status": "outside-cohort", + "note": "官网列2018起步，按既有业务排除；止血材料不能仅据生物技术类别归AI公司，模板内容及临床宣传未独立核。", + "evidenceIds": [ + "TC25-BIO-LIST", + "TC25-BIO-MIRAQULES-HOME" + ] + }, + { + "id": "TC25-BIO-06", + "name": "Nephrogen", + "url": "https://www.nephrogenbiotech.com/", + "categoryId": "C07", + "kind": "company", + "profileStatus": "readable", + "status": "outside-cohort", + "note": "YC成立2022与S2020批次时序冲突保留，但均早于研究年份；AI用于生物递送研发，赞助和未来治疗价值不作经常性软件收入。", + "evidenceIds": [ + "TC25-BIO-LIST", + "TC25-BIO-NEPHROGEN-HOME", + "TC25-BIO-NEPHROGEN-YC" + ] + }, + { + "id": "TC25-BIO-07", + "name": "PraxisPro", + "url": "https://www.praxispro.ai/", + "categoryId": "C07", + "kind": "company", + "profileStatus": "readable", + "status": "outside-cohort", + "note": "公司页列2023成立；按实际任务归生命科学专业商业软件，不视为新药研发或基础模型，不与其他Praxis同名公司合并。", + "evidenceIds": [ + "TC25-BIO-LIST", + "TC25-BIO-PRAXISPRO-HOME", + "TC25-BIO-PRAXISPRO-YEAR" + ] + }, + { + "id": "TC25-BIO-08", + "name": "Reme-D", + "url": "https://reme-d-inc.com/", + "categoryId": "C07", + "kind": "company", + "profileStatus": "readable", + "status": "outside-cohort", + "note": "官网2024活动证明更早业务，按既有业务排除；机构年份直达失败留缺，AI用途和试剂/设备收入拆分未知。", + "evidenceIds": [ + "TC25-BIO-LIST", + "TC25-BIO-REMED-HOME", + "TC25-BIO-REMED-HISTORY", + "TC25-BIO-REMED-YEAR-ACCESS" + ] + }, + { + "id": "TC25-BIO-09", + "name": "Surgicure Technologies", + "url": "https://www.surgicuretech.com/", + "categoryId": "C07", + "kind": "company", + "profileStatus": "readable", + "status": "outside-cohort", + "note": "原始SEC申报列2019组织成立，排除新公司；气道固定器械不直接认定AI公司，融资、客户ROI与收入分开。", + "evidenceIds": [ + "TC25-BIO-LIST", + "TC25-BIO-SURGICURE-HOME", + "TC25-BIO-SURGICURE-SEC" + ] + } + ] } ], "directoryRechecks": [ diff --git a/content/research/ai-companies.sources.json b/content/research/ai-companies.sources.json index 65ed961..f4ceab8 100644 --- a/content/research/ai-companies.sources.json +++ b/content/research/ai-companies.sources.json @@ -1,5 +1,5 @@ { - "version": "2026-10-30-34", + "version": "2026-10-30-35", "scopeConfirmedAt": "2026-10-30", "acceptance": "以确认的公开来源清单为边界，逐条核对并标明缺项。", "provenance": "S01—S12恢复自已提交用户的《AI公司研究_来源与分类模板》来源清单；S13—S16单列后续已使用的补充证据渠道，不将使用次数当作全量覆盖。", @@ -28,8 +28,8 @@ "techcrunch.com" ], "initialAccess": "AI栏目可读取", - "boundary": "2026首页定向3项已登记，另从AI第3—4页登记5项：3项关联公司、1项范围外、1项待核；不等全部卡片核验。另已读2025年度档案入口与AI第二页，并完整登记一篇2025企业竞赛名单32项：复用1项、范围外29项、待核2项；每项均尝试原始链接，未知与不可读保留。单篇32项不等全部200参赛者、全部分页或两年全量；RSS/API普通请求受限。 另从AI第5—6页定向4项：2项原始资料归范围外，2项原始成立/年份待核；不是全部卡片、参赛者或档案。 另逐条登记2025政府/法律名单正文11项（标题称10）：7项范围外或既有业务、4项成立/主体待核；不新增主公司或ARR，非全部200或两年档案。 另将2025金融/地产名单14项全部登记：11项范围外/既有业务，3项年份/主体/AI待核；不新增公司或收入，不等其余竞赛类别。", - "nextCheck": "继续核本篇2项的成立、主体及AI主营，优先解决Billow批次与发现年份时序、Sponstar原始年份冲突；既有业务的法律沿革及不可读项仍留缺；沿普通2025档案和AI分页扩展其余来源台账，区分参赛年、批次与公司成立年。 继续核Laplace原始年份及Eka精确注册主体；Recursive的2025/2026年份冲突保留。 继续核Honeyjar主字段与转载的年份差异、Blueprints原始可读资料与旧建筑业务主体；不把包价、演示金额或建设项目价值当ARR。 本篇待核Aparti原始成立、JustiGuide的2024/2026语义、orchestraos主体与年份及Pytho原始登记；补其余竞赛类别和年度档案，不用同名链接替代核查。 补ticker原始可读页面、Investwise主营及主体、Soundspace成立与AI实际交付；保留Genia结果收费与首页套餐的合同缺项，不把交易、返佣或客户资产年化为ARR。", + "boundary": "2026首页定向3项已登记，另从AI第3—4页登记5项：3项关联公司、1项范围外、1项待核；不等全部卡片核验。另已读2025年度档案入口与AI第二页，并完整登记一篇2025企业竞赛名单32项：复用1项、范围外29项、待核2项；每项均尝试原始链接，未知与不可读保留。单篇32项不等全部200参赛者、全部分页或两年全量；RSS/API普通请求受限。 另从AI第5—6页定向4项：2项原始资料归范围外，2项原始成立/年份待核；不是全部卡片、参赛者或档案。 另逐条登记2025政府/法律名单正文11项（标题称10）：7项范围外或既有业务、4项成立/主体待核；不新增主公司或ARR，非全部200或两年档案。 另将2025金融/地产名单14项全部登记：11项范围外/既有业务，3项年份/主体/AI待核；不新增公司或收入，不等其余竞赛类别。 另将2025生物技术名单9项全部登记：8项范围外或既有业务，1项产品与主体对应待核；不新增公司或收入，非全部竞赛类别。", + "nextCheck": "继续核本篇2项的成立、主体及AI主营，优先解决Billow批次与发现年份时序、Sponstar原始年份冲突；既有业务的法律沿革及不可读项仍留缺；沿普通2025档案和AI分页扩展其余来源台账，区分参赛年、批次与公司成立年。 继续核Laplace原始年份及Eka精确注册主体；Recursive的2025/2026年份冲突保留。 继续核Honeyjar主字段与转载的年份差异、Blueprints原始可读资料与旧建筑业务主体；不把包价、演示金额或建设项目价值当ARR。 本篇待核Aparti原始成立、JustiGuide的2024/2026语义、orchestraos主体与年份及Pytho原始登记；补其余竞赛类别和年度档案，不用同名链接替代核查。 补ticker原始可读页面、Investwise主营及主体、Soundspace成立与AI实际交付；保留Genia结果收费与首页套餐的合同缺项，不把交易、返佣或客户资产年化为ARR。 补Avara可读条款和Lumos登记号对应、其他生物技术候选的AI实际作用及地域主体链；研发、临床、审批计划和药企赞助与当前商业收入分开。", "limitation": "需追溯原始披露，部分文章受访问限制", "accessRecheckedAt": "2026-10-30" }, diff --git a/content/research/ai-income-analysis.json b/content/research/ai-income-analysis.json index da3fd88..f779aed 100644 --- a/content/research/ai-income-analysis.json +++ b/content/research/ai-income-analysis.json @@ -1,5 +1,5 @@ { - "sourceVersion": "2026-10-30-tc-finance-1", + "sourceVersion": "2026-10-30-tc-biotech-1", "asOf": "2026-10-30", "metric": "platform-mrr-usd", "sampleUnit": "product-or-business",